RYBREVANT® (amivantamab-vmjw) plus chemotherapy show 49 percent overall response rate in metastatic colorectal cancer
J&J(JNJ) Prnewswire·2024-09-14 21:45J&J(JNJ) Prnewswire·2024-09-14 21:45
R1J&J(JNJ) Prnewswire·2024-09-14 21:45 R1J&J(JNJ) Prnewswire·2024-09-14 21:45